AACR 2025 Tracker: Marengo, BriaCell, Present Promising Data

# AACR 2025 Annual Conference:
Cancer Research Breakthroughs

The American Association for Cancer Research (AACR) Annual Meeting 2025 is currently taking place from April 25-30 at McCormick Place Convention Center in Chicago, Illinois35. This premier cancer research conference has featured significant scientific breakthroughs from several pharmaceutical companies and research institutions.

Notable Research Presentations

Marengo Therapeutics has shown promising progress against colorectal cancers that are resistant to PD-1 therapies, representing a potential breakthrough for patients with limited treatment options1. This advancement addresses an important gap in current cancer treatment protocols.

BriaCell Therapeutics presented encouraging Phase III trial data for their lead immunotherapy candidate, BRIA-IMT, in treating metastatic breast cancer1. The results showed:

Progression-free survival rate of 3.67 months across 62 patients
Identification of positive biomarkers associated with better treatment outcomes
Patients with favorable changes in circulating tumor cells demonstrated improved survival (3.8 months vs. 2.4 months)
Beneficial neutrophil-to-lymphocyte ratio, a key indicator of reduced inflammation1

BRIA-IMT utilizes a genetically engineered human breast cancer cell line that has been modified to incorporate immune cell features. While its exact mechanism remains undefined, researchers hypothesize that the drug stimulates the immune system to target and destroy breast cancer cells1.

Conference Overview

The AACR Annual Meeting 2025 theme is "Unifying Cancer Science and Medicine: A Continuum of Innovation for Impact"3. The event brings together scientists, clinicians, healthcare professionals, survivors, patients, and advocates to share breakthroughs across various domains:

Population science and prevention
Cancer biology
Translational and clinical studies
Survivorship and advocacy35

Additional pharmaceutical companies presenting at the conference include GSK, Boehringer Ingelheim, Merck, and Roche, all showcasing new data for established oncology treatments and investigational drug candidates1.

The conference continues through April 30, 2025, with ongoing presentations of cutting-edge cancer research.

Sources:

1. https://www.biospace.com/drug-development/aacr-2025-tracker-gsk-boehringer-ingelheim-kick-off-meeting-with-new-data

3. https://www.aacr.org/meeting/aacr-annual-meeting-2025/

5. https://www.aacr.org/patients-caregivers/patient-advocacy/advocates-at-aacr-annual-meeting/